| Drug / Therapy | suzetrigine (VX-548) |
| Indication | moderate-to-severe acute pain sNDA |
| Decision Type | PDUFA |
| Conditions | moderate-to-severe acute pain sNDA |
| Interventions | suzetrigine (VX-548) |
Vertex Pharmaceuticals (VRTX) operates in the Gene Therapy sector. The current BTS Score is 45 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for suzetrigine (VX-548) by Vertex Pharmaceuticals (VRTX) is scheduled for June 20, 2026. This is the target date for the FDA to make a decision on this application.
suzetrigine (VX-548) is being developed by Vertex Pharmaceuticals for the treatment of moderate-to-severe acute pain sNDA. It is under FDA review.
If suzetrigine (VX-548) receives FDA approval, Vertex Pharmaceuticals (VRTX) would be able to market the drug in the United States for moderate-to-severe acute pain sNDA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for VRTX on DilutionWatch at dilutionwatch.com/stock/VRTX.html.
You can view the full BiotechSign company profile for Vertex Pharmaceuticals (VRTX) at biotechsign.com/app/company/VRTX, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.